Podcasts about drug pricing

Welcome back to Impact Theory with Tom Bilyeu! In this episode, Tom and Producer Drew dive into a dynamic conversation covering everything from unexpected dinner stories with hip-hop legends and comic creators to deep reflections on global politics, commerce, and the future of technology. Tom and Drew break down Trump's recent deals, cultural realism in foreign policy, the impact of commerce as a global connector, and the blurred lines between healthy capitalism and exploitative systems. SHOWNOTES 00:00 Middle East's Self-Led Transformation 07:39 Cultural Collisions and Misguided Interventions 31:44 Eugenics: Dark Historical Perception 44:36 "Trump's Strategic Move on Drug Pricing" 01:01:45 "Reforming Loan Structures & School Funding" 01:23:07 "Critique of Money Printing Policies" 01:35:17 "Understanding Manipulation in Economics" CHECK OUT OUR SPONSORS Vital Proteins: Get 20% off by going to ⁠https://www.vitalproteins.com⁠ and entering promo code IMPACT at check out Allio Capital: Macro investing for people who want to understand the big picture. Download their app in the App Store or at Google Play, or text my name “TOM” to 511511. ButcherBox: New users that sign up for ButcherBox will receive their choice between steak tips, salmon, or chicken breast in every box for a year + $20 off their first box at ⁠https://butcherbox.com/impact⁠ Monarch Money: Use code THEORY at ⁠https://monarchmoney.com⁠ for 50% off your first year! CashApp: Download Cash App Today:⁠ https://capl.onelink.me/vFut/v6nymgjl⁠ #CashAppPod iRestore:Give yourself the gift of hair confidence this year. For a limited time only, our community is getting a HUGE discount on the iRestore Elite when you use code IMPACT at ⁠https://irestore.com⁠ iTrust Capital: Use code IMPACTGO when you sign up and fund your account to get a $100 bonus at ⁠https://www.itrustcapital.com/tombilyeu⁠  Jerry: Stop needlessly overpaying for car insurance - download the Jerry app or head to ⁠https://jerry.ai/impact⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Francesca Bruce, Senior Editor Cathy Kelly and Editor-in-Chief Nielsen Hobbs consider European officials' opinions of President Trump's Most Favored Nation drug pricing proposal (:29), the uncertainty the plan has created and could create for the pharmaceutical industry (22:48), as well as its potential impact on the both sides of the Atlantic Ocean (27:42). More On These Topics From The Pink Sheet ‘Brainless' US MFN Policy Could Drive Pharma Investment To Europe: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/brainless-us-mfn-policy-could-drive-pharma-investment-to-europe-Z3FC7WBPKNF2LLG4YVZK3RBDUA/ US ‘Most Favored Nation' Pricing Could be Game Changer for Drug Access In Germany: https://insights.citeline.com/pink-sheet/geography/europe/us-most-favored-nation-pricing-could-be-game-changer-for-drug-access-in-germany-XFXD72XUSBE7VNLRMRSRQQGU5Q/ US Most Favored Nations Policy: Higher Drug Spending In Germany Is ‘Difficult To Imagine': https://insights.citeline.com/pink-sheet/geography/europe/us-most-favored-nations-policy-higher-drug-spending-in-germany-is-difficult-to-imagine-QYQGDAMNH5A3HK4YWHUYFJCWME/ Could EU Collective Procurement Counter US Most Favored Nation Policy?: https://insights.citeline.com/pink-sheet/could-eu-collective-procurement-counter-us-most-favored-nation-policy-WPQOHPWQ3NF55NYDKT5KMU7AEY/ US ‘Most Favored Nations' Drug Pricing Policy Will Jeopardize Innovation In Europe: https://insights.citeline.com/pink-sheet/us-most-favored-nations-drug-pricing-policy-will-jeopardize-innovation-in-europe-TR52C5V6GVDSJBOTCEJ7T74FB4/ New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France: https://insights.citeline.com/pink-sheet/risk-sharing-agreements-greater-transparency-in-pricing-what-us-most-favored-nations-policy-could-OYEHJIF6LJCQZDL6VJHATV77JA/ Crisis Or Opportunity? US MFN Policy Could Test Japan's Appetite For Reforms: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/crisis-or-opportunity-us-mfn-policy-could-test-japans-appetite-for-reforms-3OTVRHXSOFFIJARSNHPWZ7SBJ4/

Subscribe to UnitedHealthcare's Community & State newsletter.Health Affairs' Rob Lott interviews Keith Drake of Greylock McKinnon Associates about his recent paper that explores trends in authorized generic drug launches and the effects observed on competition in pharmaceutical markets in the US. Order the June 2025 issue of Health Affairs.Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcast Subscribe to UnitedHealthcare's Community & State newsletter.

Stakeholders from across the healthcare industry, including members of Congress, the US Food and Drug Administration, and the Center for Medicare and Medicaid Services, recently convened in Washington D.C. for the Medical Device Manufacturers Association (MDMA) Annual Meeting. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott, Nate Beaton, and Bill McConagha, and associate Danny Machado share their key takeaways from the meeting, including compliance hot topics and what the industry can expect in terms of regulatory enforcement in 2025.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

A conversation with Vinay PatelThere are too many barriers in the pursuit of health: financial, infrastructural, systematic… American healthcare is set up to fail the patients it needs to prioritize.Welcome Vinay Patel, a forward thinking pharmacist and healthcare entrepreneur who founded MakoRx, a company focused on disrupting traditional drug pricing models and improving pharmacy access.He saw a system that failed patients - charging exorbitant prices for cheaply-made drugs - until he decided to break with the status quo and set about creating a new model, rooted in transparency and focused on patient outcomes, not profit.— —We spoke about how drug pricing actually works, why costs vary so wildly, and what needs to happen to make healthcare more affordable and accessible - looking ahead to what the future of pharmacy might hold.https://www.linkedin.com/company/makorx Follow me on Instagram and Facebook @ericfethkemd and checkout my website at www.EricFethkeMD.com. My brand new book, The Privilege of Caring, is out now on Amazon! https://www.amazon.com/dp/B0CP6H6QN4

Dealmaking by a pair of pharmas has given the biotech industry its best day of transactions in months, tallying nearly $13 billion in guaranteed payments across two deals. On the latest BioCentury This Week podcast, BioCentury's analysts discuss how the takeout of Blueprint Medicines for $9.1 billion up front gives Sanofi a drug for a rare immunological disorder and bolsters the French pharma's already strong presence in immunology. The analysts also assess the $3.5 billion partnership between BioNTech and Bristol Myers Squibb for an asset targeting cancer's hottest target, PD-(L)1 x VEGF, and underwhelming data from the leading asset against the target, PD-1 x VEGF bispecific ivonescimab, from Summit and Akeso Inc. Those data coincided with the kick-off of the American Society of Clinical Oncology (ASCO) meeting in Chicago, where almost a dozen companies were presenting readouts for another hot target, CLDN18.2. Evopoint is among the companies; its program recently attracted Astellas as a partner. Meanwhile, the biopharma industry is racing to counter the White House's most favored nation drug pricing strategy. BioCentury's Washington analyst, Steve Usdin, explains the urgency and details some of industry's options.View full story: https://www.biocentury.com/article/656097#biotech #biopharma #pharma #lifescience #deals00:00 - Introduction04:39 - Sanofi Buys Blueprint09:22 - BMS-BioNTech20:01 - Hot Targets23:40 - Drug PricingTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

This podcast will provide members with analysis of the Administration's actions on drug pricing to date, including proposed tariffs and two separate Executive Orders (EOs). We'll talk through key elements of the EO on Most Favored Nation pricing, how it might intersect with the earlier, more general EO on drug pricing, and what these policy shifts could mean for members. We'll also discuss how potential tariffs on pharmaceuticals might further complicate the drug pricing picture. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This week in the Breakroom, Amy Kelbick joins Maddie News to discuss recent actions by the Trump Administration and Congress on lowering the cost of prescription drugs.

USTR seeking comments on drug pricing policies that are unfair to Americans. Listen for more info on Two Minutes in Trade. 

Pfizer stole the headlines this week with a pact worth up to $6 billion with Chinese biotech 3SBio for a PD-1/VEGF candidate just three months after inking a clinical trials collab for a similar drug with Summit Therapeutics. It's the largest Chinese licensing deal in recent memory, as pharmas continue to turn to the country to fill their pipelines.  Also on Tuesday, the Department of Health and Human Services offered a smidge more detail on President Donald Trump's Most Favored Nation executive order. A press release explained that drug prices will be tied to the lowest price in certain countries with a GDP at least 60% that of the U.S. and that the effort will focus on branded drugs.   Over at the FDA, the strategy around COVID-19 vaccines is evolving. According to an editorial published in the New England Journal of Medicine Tuesday by FDA Commissioner Marty Makary and CBER director Vinay Prasad, future COVID-19 approvals will focus on adults over 65 and high-risk individuals six months to 64 years old—a strategy they say will better align the U.S. with other high-income nations. This is also in sync with the Novavax approval, which came in Friday after a few delays.   Meanwhile, the FDA's Oncologic Drugs Advisory Committee (ODAC) is currently in the midst of a two-day meeting, but acquiring the necessary expertise was “absolute chaos,” according to an agency insider who spoke with BioSpace. This is partly due to the decimation of an FDA office that includes staff responsible for screening scientific and therapeutic area experts for conflicts of interest.  Going back to last week—which seems like a year ago at this point—we were somewhat shocked to learn that the CEO of one of the world's most valuable pharma companies is on his way out. Friday morning, Novo Nordisk announced that CEO Lars Fruergaard Jørgensen will be leaving the company after eight years at the helm. After peaking last June at about $155 apiece, the obesity leader's shares are currently worth just $68. Novo said the decision for Jorgensen to leave was mutual, but Jorgensen was not made available to speak on a call following the announcement.  Finally, a couple of milestones are worth noting: First, the Alzheimer's space got a big win on Friday when the FDA approved the first blood-based test for the disease—news that could be a boon to Eli Lilly's Kisunla and Biogen & Eisai's Leqembi. And second, a nine-month-old boy named KJ with a disease called CPS1 deficiency that affects just 1 in 1.3 million U.S. babies was treated with a single-use CRISPR treatment created just for him. It's an incredible story that highlights just how far gene editing has come, but it also highlights a rare disease crisis, with these sorts of ultra- and nanorare diseases lacking the necessary financial incentive to motivate biopharma's focus.   

Understanding Trump's Executive Order on Drug Pricing | ShiftShapersIn this episode of ShiftShapers, host David A. Saltzman welcomes Tiffany Ryder, emergency medicine PA, host of Healthcare Liberty Lab, and writer at Red Flag Hero on Substack. Tiffany breaks down President Trump's executive order on drug pricing and what it could mean for patients, providers, and pharmaceutical companies.She explores key issues like most favored nation pricing, transparency in drug costs, and the role of PBMs and middlemen. Drawing from her frontline experience and policy knowledge, Tiffany explains how these changes may impact everything from consumer behavior to research and development in the pharmaceutical world.

About this episode: This week, President Trump signed an Executive Order aimed at lowering prescription drug costs. In this episode: a look at why the U.S. spends three to four times more for drugs than many peer countries, its current approach to drug pricing policy, the directives laid out in the Executive Order, and how other countries negotiate their prices. Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University. Guest: Dr. Gerard Anderson is an expert in health policy and a professor in Health Policy and Management and International Health at the Johns Hopkins Bloomberg School of Public Health. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs at the Johns Hopkins Bloomberg School of Public Health. Show links and related content: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients—Executive Order, The White House The Potential Impacts of Cuts to Medicaid—Public Health On Call (March 2025) What's Next For Prescription Drug Pricing?—Public Health On Call (February 2023) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed

AAF President Douglas Holtz-Eakin and Director of Health Care Policy Michael Baker join us to discuss the House committee markups of the reconciliation bill and President Trump's new executive order on drug prices. Apple: podcasts.apple.com/us/podcast/the-…st/id1462191777 Spotify: open.spotify.com/show/7aWwYw3EKPmTqLQMbRGR2e

Drug Pricing; China; Budget; Trump in ME; Houthis; S. African Refugees; Milei | Yaron Brook Show

In this episode, Scott Becker is joined by Becker's Healthcare Editor-in-Chief Laura Dyrda to discuss major healthcare developments, including a new executive order targeting drug prices, potential Medicaid cuts, and OpenAI's new framework for evaluating AI in clinical settings.

President Donald Trump unveiled a sweeping drug pricing policy this week, seeking to lower drug prices in the U.S. by up to 80% through a reprisal of the Most Favored Nation rule he attempted to introduce in his first term. The rule would essentially link U.S. prices to those paid in other nations where medications are cheaper. Biopharma reaction was one of tentative relief, with BMO Capital Markets analysts suggesting the executive order had “more bark than bite.” Meanwhile, the Centers for Medicare and Medicaid Services announced that among the next 15 drugs to undergo IRA-prescripted price negotiations could be drugs payable through Medicare Part B, and not just Part D, where the first two rounds have applied.  Into all of this action steps Vinay Prasad, the outspoken oncologist and hematologist who was named last week as the next director of the FDA's Center for Biologics Evaluation and Research. While the S&P Biotech ETF fell by more than 5% upon the news, overall reaction was fairly measured, with cell and gene therapy executive Audrey Greenberg summing up Prasad's selection as “anything but a status quo appointment.”  Over in the weight loss and obesity space, Eli Lilly can't seem to lose. This weekend, Lilly announced full data from a head-to-head trial showing a “superior benefit-to-risk ratio” for its Zepbound over Novo Nordisk's Wegovy. And last week, the Indiana-based pharma won a court battle against compounders when a judge sided with the FDA, stating that tirzepatide—the active ingredient in both Zepbound and diabetes sister drug Mounjaro—was no longer in shortage. Add on a presidential shoutout during Trump's Monday press conference for its U.S. manufacturing investments, and it really was Lilly's week.  Flying less high are some 2,000 Bayer employees who lost their jobs in the first quarter of 2025 as part of the company's new operating model, which is intended to make Bayer “much more agile.” On a less direct flight is Galapagos, which reversed course on plans to spin out a portion of the company and find a new CEO. Instead, CEO Paul Stoffels will make a quicker exit and the Belgian biotech could sell off its cell therapy assets as it looks to build up a new pipeline in house, having abandoned the spinout idea altogether. Stay tuned.  Finally, in ClinicaSpace this week, we took a deep dive into the HIV treatment space, where companies like Gilead and Immunocore are targeting a cure, while the Trump administration slashes funding for HIV research.  

Episode DescriptionAudra Moran is the President and CEO of OCRA—Ovarian Cancer Research Alliance—which means she spends her days doing things most of us wouldn't survive five minutes doing: merging nonprofits, leading national patient support programs, funding lifesaving research, surviving pharma grant hell, and trying to reach every woman in America who might be slipping through the cracks. We talk about her time working with the Helen Keller National Center (yes, she knows finger spelling), her accidental journey into cancer nonprofit leadership, the weirdness of dermoid cysts, the ridiculousness of writing grants, and the absolute hellscape of diagnosis delay. Oh, and the fallopian tubes. You'll never look at them the same way again.This episode is funny, raw, deeply personal, and loaded with Gen X movie references and random facts about Paul Rudd, Terminator 2, and flipbook apps at 3am. Audra drops wisdom, humility, and a few hot takes on AI, advocacy, and what it really means to lead when the boulder keeps rolling downhill.RELATED LINKSAudra Moran on LinkedInOvarian Cancer Research Alliance (OCRA)Audra's profile on OCRACURE Today interview: Leading the FightOCRA + AI & Data: Overlooked PodcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Logan is joined by Zach Weinberg (Co-Founder/CEO @ Curie.Bio) and Derek Thompson (writer at The Atlantic) for a candid discussion on the state of U.S. healthcare and scientific progress. They unpack what went right, and wrong, with COVID vaccine policy, the public backlash against mRNA technology, and the ripple effects on trust in science. The conversation also dives into the real reasons behind NIH budget cuts, the economics of drug discovery, and the business incentives in medical R&D. It's a sharp, thought-provoking look at the intersection of policy, innovation, and public perception. (00:00) Introduction to Drug Pricing in the US (00:23) Broad Healthcare Topics and Open-Ended Discussion (02:37) COVID-19 Vaccines: Successes and Public Perception (06:21) The Evolution of COVID-19 and Vaccine Efficacy (07:59) Public Policy and Vaccine Mandates (13:10) Impact of School Closures and Public Sentiment (19:23) NIH Funding and the Importance of Basic Research (25:04) Challenges in Science Funding and Public Perception (35:19) Government vs. Private Investment in Science (36:40) Operation Warp Speed: A Case Study (39:07) Antibiotic Resistance Crisis (43:22) The Drug Pricing Debate (44:05) Challenges in Drug Discovery (54:06) Regulatory Hurdles in Medical R&D (58:06) The Future of Drug Development (01:04:19) Concluding Thoughts Executive Producer: Rashad Assir Producer: Leah Clapper Mixing and editing: Justin Hrabovsky Check out Unsupervised Learning, Redpoint's AI Podcast: https://www.youtube.com/@UCUl-s_Vp-Kkk_XVyDylNwLA

Social Security Works Exec. Dir. Alex Lawson on Trump's Executive Order, "Delivering most-favored-nation prescription drug pricing to American patients" -- another scam to cut Medicaid and Medicare.Subscribe to our Newsletter:https://politicsdoneright.com/newsletterPurchase our Books: As I See It: https://amzn.to/3XpvW5o How To Make AmericaUtopia: https://amzn.to/3VKVFnG It's Worth It: https://amzn.to/3VFByXP Lose Weight And BeFit Now: https://amzn.to/3xiQK3K Tribulations of anAfro-Latino Caribbean man: https://amzn.to/4c09rbE

The Trump drug price reduction bill is a scam. The tariff deal between Trump and China only raises prices for the working class. The Trump administration charters flights to bring white South Africans.Subscribe to our Newsletter:https://politicsdoneright.com/newsletterPurchase our Books: As I See It: https://amzn.to/3XpvW5o How To Make AmericaUtopia: https://amzn.to/3VKVFnG It's Worth It: https://amzn.to/3VFByXP Lose Weight And BeFit Now: https://amzn.to/3xiQK3K Tribulations of anAfro-Latino Caribbean man: https://amzn.to/4c09rbE

When Trump brags, he tends to have a loose tongue that often tells the truth by accident. He confesses and infers that tariffs and drug price reductions are for tax cuts.Subscribe to our Newsletter:https://politicsdoneright.com/newsletterPurchase our Books: As I See It: https://amzn.to/3XpvW5o How To Make AmericaUtopia: https://amzn.to/3VKVFnG It's Worth It: https://amzn.to/3VFByXP Lose Weight And BeFit Now: https://amzn.to/3xiQK3K Tribulations of anAfro-Latino Caribbean man: https://amzn.to/4c09rbE

Marc Cox talks with Dr. William Soliman, Founder and CEO of the Accreditation Council for Medical Affairs, about the administration's historic push to lower drug prices—particularly for Medicare patients. Dr. Soliman breaks down why Americans pay up to 15 times more for medications than those in other countries, the role of pharmacy benefit managers in inflating costs, and how pharmaceutical companies navigate R&D timelines and profit windows. They also explore the market dynamics behind global drug pricing and challenges facing privately insured patients in accessing life-saving medications.

Fox News' Chad Pergram recaps President Trump's visit to Saudi Arabia, where he met with political and business leaders and signed new agreements. Ryan Wiggins of Wiggins America weighs in on the political implications of the new book Original Sin, which details internal concerns over President Biden's physical condition. Also covered: the fallout from progressive lawmakers like AOC attempting to enter an ICE detention facility. In studio, Bob Kershaw and Thomas Helbig share retirement strategies ahead of their upcoming April 20th seminar, focusing on protecting savings during volatile markets.

Dr. Lisa Mathew interviews Dr. Brittany Panico, a rheumatologist in Colorado Springs who recently wrote an op-ed calling for reforms to the 340B program to require more transparency and reporting on how 340B discounts are passed on to patients. The 340B Program is a federal drug pricing program that allows certain hospitals and clinics to buy medications at steep discounts to support medication access for underserved patients, with the expectation that these savings would be passed on to patients. But critics argue that the program's growth has led to unintended consequences, such as market consolidation. And some studies suggest that 340B discounts may not translate into increased care or lower costs for vulnerable populations. Join Dr. Mathew and Dr. Panico as they discuss Dr. Panico's experience as an employed physician in a 340B hospital system and as an independent physician, and how the lack of oversight in the program may be making it harder for specialists to deliver the best patient care. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 77, presented by TissueCypher from Castle Biosciences

Thank you Gail Shields, Jane B

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The White House has announced a new drug pricing policy that includes the revival of the most favored nations rule and extends to the private markets, leveraging the patent system, drug importation, and more. Meanwhile, Lilly's Zepbound has been found to have a superior benefit-risk ratio compared to Novo's Wegovy, BMS and Sanofi settle a Plavix lawsuit with Hawaii for $700 million, and biopharma companies are focusing on developing a cure for HIV as federal funding for related research is being cut. Sino Biological offers comprehensive solutions for autoimmune diseases, and Roche promises a $300 million investment in China production after a multibillion-dollar investment in the US. On the other hand, Lexeo and IGM have both announced significant layoffs. Novartis CEO has expressed concerns about Trump's pricing controls.Funding for HIV-related research and infrastructure is being cut by the Trump administration, leading biopharma companies like Gilead and Immunocore to focus on finding a cure for HIV. In the field of neurology, there is a need for more precise diagnostic tools to effectively treat neurodegenerative conditions. The new HHS vaccine requirement has been criticized by leading vaccine physician Paul Offit as potentially being anti-vaccine activism disguised as policy. Companies like Novartis, Bayer, and AstraZeneca are exploring new indications and innovations in radiopharmaceuticals, hoping to capitalize on a market that could reach $16 billion by 2033. The FDA has faced delays in reviewing certain drugs, while biotech stocks have fallen after the appointment of Vinay Prasad to succeed Marks at CBER. Vertex has decided to abandon AAV in the gene therapy space.Upcoming events include a webinar on surviving and thriving in the biotech downturn. Job opportunities in the biopharma industry include positions at Takeda, Daiichi Sankyo, and AbbVie. Heather McKenzie, senior editor at BioSpace, is open to suggestions for future coverage topics in neuroscience, oncology, cell & gene therapy, metabolic, or other areas.

Stocks surging across the board after the U.S. and China agreed to temporarily slash tariffs. The sectors and stocks seeing the biggest moves, and what the news means for the Fed's rate policy. Plus Drugmakers on the clock, as President Trump signs an executive order aimed at lowering prescription drug cots. How the pharma space is reacting, and why one top health care analyst isn't too worried about the policy changes.Fast Money Disclaimer

In this episode of Good Morning Liberty, hosts Nate Thurston and Charles 'Chuck' Carhartt Thompson discuss a range of hot topics starting with Trump's alleged new trade deal with China. They delve into the details, criticizing the lack of real concessions and Trump's claims of a 'total reset' in tariffs. The duo also talks about Trump's new executive order on reducing prescription drug costs, exploring the implications of a 'Most Favored Nation' policy and potential pitfalls including medication shortages and economic ramifications. Alongside these big-ticket items, the episode also touches on various weekend updates including a $400 million plane gift to the Department of Defense, a discussion on habeas corpus, ICE activities, and more. Join Nate and Chuck as they provide their unique Libertarian perspective on current events. (03:50) China Trade Deal Analysis (09:28) Trump's Executive Order on Prescription Drugs (25:16) Adjustments for Unhealthy America (25:37) Government's Role in Drug Pricing (27:04) Global Price Disparities (29:35) Pharmacy Benefit Managers and Market Inefficiencies (30:48) Direct-to-Consumer Sales and Mark Cuban's Initiative (31:52) Generic vs. Name Brand Medications (32:57) Trump's Most Favored Nation Policy (38:57) Potential Consequences of Price Controls (43:26) Free Market Solutions and Government Regulation (46:48) Conclusion and Final Thoughts   Links:   https://gml.bio.link/   YOUTUBE:   https://bit.ly/3UwsRiv   RUMBLE:   https://rumble.com/c/GML   Check out Martens Minute!   https://martensminute.podbean.com/   Follow Josh Martens on X:   https://twitter.com/joshmartens13   Join the private discord & chat during the show!   joingml.com   Bank on Yourself bankonyourself.com/gml   Get FACTOR Today! FACTORMEALS.com/factorpodcast     Good Morning Liberty is sponsored by BetterHelp! Rediscover your curiosity today by visiting Betterhelp.com/GML (Get 10% off your first month)     Protect your privacy and unlock the full potential of your streaming services with ExpressVPN. Get 3 more months absolutely FREE by using our link EXPRESSVPN.com/GML  

Dan Snell, an expert on politics and leadership, joins the show to discuss the potential implications of tax legislation, particularly the proposed tax increase on high-income earners. With Mike Johnson's goal to pass the bill by Memorial Day, Dan breaks down the legislative strategy and what it means for both Republican and Democratic responses. The conversation also covers President Trump's executive order on drug pricing, exploring the reasons behind high drug prices in the U.S., including research and development costs, and how the "most favored nation" status could impact pricing. Dan also discusses the challenges of balancing pharmaceutical pricing with funding for research, the role of government regulation, and the broader economic policy implications of these issues.

Marc Cox talks to Hans von Spakovsky about the Trump administration's push for an executive order to lower drug prices by matching international rates. They discuss the complexities of the FDA's drug approval process, the impact of regulatory burdens on pharmaceutical innovation, and the concerns over removing profit incentives for drug companies. Hans also critiques federal district court judges issuing nationwide injunctions, discusses presidential authority on foreign policy, and the potential for Supreme Court intervention in legal challenges.

In Hour 1, Marc Cox explores major global developments, including a new China trade deal, President Trump's drug pricing strategy, and peace efforts in the Middle East. Kim St. Onge wraps the hour with “Kim on a Whim,” spotlighting South Carolina's execution of Mikal Mahdi and the ongoing debate over firing squads. Hour 2 features Hans von Spakovsky of the Heritage Foundation breaking down legal questions around drug pricing and nationwide injunctions. Nichole Murray reports on the stock market and a quirky Krispy Kreme–Pac-Man story. The hour closes with “In Other News,” including British comedian Stuart Lee's controversial views on Trump and fascism in America. In Hour 3, Lucas Tomlinson joins to recap President Trump's diplomatic trip to Saudi Arabia and new developments in the Middle East and China. Dan Snell discusses the impact of a proposed millionaire tax and the delicate balance between drug affordability and pharmaceutical innovation. The hour ends with reactions to the China trade deal, media bias, and Charles Barkley's comments on transgender athletes—plus a fun segment on cooking crabs in an air fryer. Hour 4 brings in Jessie Jane Duff to analyze Trump's trade policy, Democratic challenges, and military and immigration issues. Tom Ackerman provides a spirited Cardinals update, a look at UFL BattleHawks attendance, and commentary on online threats against athletes like Max Homa and Lance McCullers. The hour wraps with stock market analysis and Trump's drug pricing push.

This Day in Legal History: Harry Blackmun Confirmed to SCOTUSOn May 12, 1970, the U.S. Senate unanimously confirmed Judge Harry A. Blackmun to the Supreme Court, filling the vacancy left by Justice Abe Fortas. Nominated by President Richard Nixon, Blackmun had previously served on the U.S. Court of Appeals for the Eighth Circuit and was considered a moderate, scholarly jurist. His confirmation marked the culmination of a tumultuous series of failed nominations for the seat, including two rejections by the Senate, making Blackmun's 94–0 approval a moment of bipartisan relief.Blackmun would go on to serve nearly a quarter-century on the Court, authoring over 700 opinions. He is perhaps best known for writing the majority opinion in Roe v. Wade (1973), which recognized a constitutional right to abortion. The decision would shape political and legal debates for decades and define Blackmun's legacy, despite his broader jurisprudential contributions. Over time, he evolved from a judicial centrist to one of the Court's more liberal voices, especially on issues of individual rights and the death penalty.After retiring in 1994, Blackmun remained active in legal education and public service until his death in 1999. The Library of Congress released his extensive papers in 2004, providing scholars with a revealing look into the internal workings of the Court during his tenure. His former clerks, some of whom became influential legal figures themselves, publicly remembered him for his deep humanity and commitment to justice. Blackmun's confirmation anniversary serves as a reminder of how judicial legacies can transcend the expectations of those who appoint them.U.S. District Judge Susan Illston issued a temporary 14-day halt on the Trump administration's federal government restructuring plan, citing a lack of congressional authorization for mass layoffs and agency overhauls. The order came in response to a lawsuit filed by unions, nonprofits, and local governments opposing the large-scale “reductions in force” initiated by the Department of Government Efficiency (DGE), led by Elon Musk. Judge Illston emphasized that the president cannot broadly restructure federal agencies without clear approval from Congress. The plaintiffs submitted extensive evidence showing critical services being disrupted, including nearly complete staff terminations at the National Institute for Occupational Safety and Health in Pittsburgh. Similar losses were reported at Head Start, the Farm Service Agency, and the Social Security Administration. Illston found the plaintiffs likely to succeed on the merits of several claims, including violations of administrative law and overreach by DGE, the Office of Management and Budget, and the Office of Personnel Management. The administration's efforts, ordered in February by Trump, aim to automate services, eliminate redundant roles, and reduce federal personnel. Critics argue the changes are destabilizing and harmful to community services. Illston's ruling aims to preserve the status quo while legal challenges proceed, with a hearing on a potential preliminary injunction scheduled for May 22.Judge orders temporary halt to Trump administration's government overhaul | ReutersRumeysa Ozturk, a Turkish PhD student at Tufts University, returned to Massachusetts after being held for over six weeks in U.S. immigration custody in Louisiana. Her arrest stemmed from a revoked student visa, which the government linked to an opinion piece she co-wrote criticizing Tufts University's response to the war in Gaza and urging divestment from companies tied to Israel. Ozturk was apprehended by masked officers in Somerville, Massachusetts, and was quickly transferred from Vermont to a detention facility in Louisiana. Her legal team, including the ACLU, argued her detention was a retaliatory act against constitutionally protected speech, aimed at silencing pro-Palestinian voices on campus.U.S. District Judge William Sessions granted her release after determining she had strong grounds for claiming her constitutional rights were violated. Upon arrival at Logan International Airport, Ozturk expressed relief and gratitude, thanking supporters and calling attention to other detained women. Representative Ayanna Pressley condemned the detention as a politically motivated act of intimidation, citing inhumane conditions and medical neglect during Ozturk's confinement. The case has drawn national attention amid broader efforts by the Trump administration to deport campus activists engaged in pro-Palestinian advocacy.Tufts student returns to Massachusetts after release from immigration custody | ReutersOver the weekend Newark Mayor Ras Baraka was arrested and charged with trespassing at the Delaney Hall immigration detention center in New Jersey during an unannounced visit by three Democratic members of Congress. U.S. Immigration and Customs Enforcement (ICE) agents detained Baraka after a scuffle at the facility's gate while a bus of detainees was arriving. Representatives Bonnie Watson Coleman, LaMonica McIver, and Robert Menendez Jr. were also present and said to have been jostled during the confrontation. According to ICE and the Department of Homeland Security, the group's uncoordinated attempt to enter the site was unsafe and politically motivated.Baraka, who is campaigning for governor, stated after his release that he was there to support the lawmakers and did not cross into restricted areas. His supporters and congressional aides claim he remained outside the facility's fence and that ICE exaggerated the incident. DHS accused the group of endangering detainees and law enforcement, while the lawmakers insisted they were exercising lawful oversight powers. The detention center, operated by the GEO Group, has faced criticism from immigrant rights advocates for allegedly lacking local permits and operating against community wishes. The controversy has become entangled in Baraka's gubernatorial campaign, spotlighting tensions over immigration policy and the role of private detention facilities.New Jersey mayor charged with trespassing at US immigration detention center | ReutersPresident Donald Trump announced plans to slash U.S. prescription drug prices to match the lowest prices found internationally, prompting a global selloff in pharmaceutical stocks. In a post touting cuts of “59%, PLUS!,” Trump previewed an executive order mandating a “most-favored nation” pricing rule. This would require that Americans pay no more than citizens in the cheapest country for the same medication—a move that starkly contradicts the administration's prior market-driven rhetoric, now seemingly embracing a form of price fixing. Investors, analysts, and drugmakers scrambled to assess the implications, especially since Medicare and Medicaid represent a major share—around 40%—of U.S. drug spending.The proposed pricing shift offers manufacturers two theoretical paths to comply: lower U.S. drug prices to align with cheaper countries like France or Japan, or raise prices overseas to maintain U.S. revenue levels. It remains unclear which route companies will choose, but economic incentives suggest they'll resist U.S. price drops by inflating foreign costs instead. Trump framed the move as restoring fairness to American consumers, whom he described as having long subsidized global drug development. The executive order follows a prior, unsuccessful attempt during his first term to peg Medicare prices to international benchmarks—a plan struck down in court for procedural flaws.The Inflation Reduction Act already initiated drug price negotiations under President Biden, but Trump's new approach could broaden the scope or accelerate the effort. However, legal and legislative obstacles remain, especially since the administration cannot set prices for the commercial market without congressional support. Analysts are watching closely for whether the policy targets just Medicare, specific drug types, or a wider range. Meanwhile, critics note the contradiction in Trump's newfound support for a centralized pricing strategy after years of decrying government interference in markets.Trump Vows US Drug Price Cuts of Up to 80% in Industry Blow (2) This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Thank you Earl Brownlee, Shelly Barbal, Alexa, Suzanne Sturrock, and many others for tuning into my live video! Join me for my next live video in the app.* Social Security Works Exec Dir discusses Trump's new pseudo-populist Drug Pricing reduction scam: Alex Lawson discusses Donald Trump's latest Executive Order, “Delivering most-favored-nation prescription drug pricing to American patients,” as anoth… To hear more, visit egberto.substack.com

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA is planning to fully integrate AI into their decision-making process by June 30, with individual centers starting the rollout immediately. Sanofi has cut off its antibody partner, leading to an 80% reduction in headcount at IgM Biosciences. The FDA has faced delays, including missing review dates for GSK's Nucala. President Trump is expected to unveil a drug pricing plan on Monday that has been criticized by big pharma and patient groups. Lotte Biologics offers end-to-end services for ADC manufacturing in Syracuse, NY. Rallybio, Insitro, Shape, and Vor have all downsized their workforces.

Don't fall for it! Deroy and Annie decry why common sense seems to require so much bravery these days.

Christine Verini is a pharmacist by training, a nonprofit CEO by title, and an unapologetic empath by design. She now leads CancerCare, one of the oldest, least-known, and most impactful organizations in the country that actually helps real cancer patients deal with the practical garbage no one likes to talk about—like paying rent, affording a ride to chemo, or feeding their kids.We talk about her career pivot from industry to impact, what it's like trying to scale empathy without losing your soul, and the daily gut-punch of knowing there are millions of people who still have no idea that CancerCare exists. Christine gets real about leadership, advocacy, burnout, and why being “pan-cancer” matters more than ever in a world obsessed with biomarkers, buckets, and branding.She also dishes on what AI gets dead wrong, what patients actually want when they call for help, and why “ghosting” someone with cancer is still a thing. Buckle up. This one's packed with heart, brains, and a little righteous rage.RELATED LINKSCancerCareChristine Verini on LinkedInChristine's CEO Announcement – PR NewswireCancer Health 25: Christine VeriniChristine on HealthyWomenBIO Convention Speaker ProfileFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Among the formerly undruggable targets gaining translational momentum, SMARCA2 has intrigued researchers for its potential to treat challenging solid tumors. On the latest BioCentury This Week podcast, BioCentury's editors zero in on preclinical research supporting different degraders of SMARCA2 at this year's American Association for Cancer Research (AACR) annual meeting.They also discuss takeaways from Editor in Chief Simone Fishburn's conversation with David Baker, the Nobel-prizewinning pioneer in protein design, and Steve Usdin reports that pharmaceutical industry executives are in a state of alarm over President Trump's push to include a “most favored nation” policy for Medicaid drug purchases in budget reconciliation legislation. Usdin also discusses why industry executives are confident of a fix for the Inflation Reduction Act's “pill penalty” and FDA Commissioner Marty Makary's decision to reject proposals to reorganize the agency. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/655851#biotech #biopharma #pharma #LifeScience #RandD #DrugDevelopment #AACR #SMARCA200:01 - Sponsor Message: Jeito Capital03:01 - AACR Spotlight11:21 - David Baker Protein Design19:12 - Trump's Drug Pricing PlanTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

The “Lowering Drug Prices by Once Again Putting Americans First” Executive Order addresses various FDA matters, such as importation from Canada and accelerated approval of generics and biosimilars. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott, Ben Haas, and Bill McConagha analyze these FDA implications, and explore how the EO overlaps with five drug pricing bills championed by Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa). Also check out Chris's interview with Life Sciences IP Review about industry impacts of the Grassley bills. And yes, it's back: Read our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

Jacob and Nikhil sit down with Otto Sipe. Otto is the CEO and Co-Founder of Photon Health, which enables patients to select their own pharmacies with price and inventory transparency. The company has raised over $16 million from investors including Flare Capital Partners and Notation Capital. They discuss where pharmacies and PBMs are headed, the evolution of E-Prescribing, the impact of GLP-1s & AI, and more. (0:00) Intro(0:51) History and Evolution of E-Prescribing(3:02) Challenges in Current E-Prescribing Systems(6:28) Photon Health's Innovative Approach(8:17) Patient and Provider Behavior Changes(11:21) Pharmacy Industry Landscape and Future(13:43) Interactions with PBMs and Market Dynamics(16:48) Future of PBMs and Drug Pricing(20:38) Quality and Marketplace Experience in Pharmacies(23:30) Advising Independent Pharmacies for Future Success(24:24) Challenges and Strategies in Retail Pharmacy(25:45) Pharmacy Economics and Supply Chain Issues(30:21) The Role and Potential of Pharmacists(36:01) AI in Pharmacy: Photon's Approach(38:28) Quickfire Out-Of-Pocket: https://www.outofpocket.health/

Jennifer Finkelstein is not here for your pity, your pinkwashed slogans, or your performative awareness campaigns. She's a 20-year young adult breast cancer survivor who turned trauma into a blueprint for action and built 5 Under 40, a no-BS nonprofit supporting women diagnosed with breast cancer under 40.In this episode, we go full Gen X therapy session—from SNL nostalgia and cold caps to the absurdity of finding out you have cancer while looking for the remote. Jen drops real talk about founding a nonprofit when nothing existed for her age group, why mental health support isn't optional, and how passing down designer scarves can mean arming someone for battle.If you're looking for honesty, grit, and a few inappropriate jokes about gastroenterology, this one's for you. You'll laugh, you might cry, and you'll definitely leave knowing why Jennifer Finkelstein is a survivor, a fighter, and a damn legend.RELATED LINKS5 Under 40 FoundationJennifer Finkelstein on LinkedInAbout 5 Under 40: Board of DirectorsDan's Papers: 5 Under 40 Supports Young Breast Cancer SurvivorsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.Let me know if you want shorter pull quotes, audiogram text, or promotional copy for LinkedIn, Instagram, or your newsletter.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie, a pharmaceutical company, has criticized President Trump's drug pricing proposal despite reporting strong earnings this quarter. The company is facing challenges with declining sales of its drug Humira and a struggling aesthetics business. Meanwhile, Gilead is moving forward with the launch of its HIV drug despite macro pressures in the industry. FDA Commissioner Marty Makary's recent statements have been fact-checked, with some contradictions emerging.In other news, SpringWorks is potentially being bought out by Merck KGaA for $3.5 billion. Wacker Biotech is offering services for advanced therapies. Stay tuned for more updates on these developments in the pharmaceutical and biotech sectors.

In this episode, Tudor and Tim Murtaugh discuss the implications of the Biden pill penalty, a provision in the Inflation Reduction Act that negatively impacts the pharmaceutical industry and healthcare costs. They explore how this legislation discourages the development of cheaper, more effective medications, leading to increased healthcare costs and lost life years. The conversation also touches on the role of China in pharmaceutical development, the unintended consequences of legislation, and the importance of intellectual property laws in protecting creators. The Tudor Dixon Podcast is part of the CLay Travis & Buck Sexton Podcast Network. For more visit TudorDixonPodcast.comSee omnystudio.com/listener for privacy information.

The Hidden Math Behind Drug Pricing: Why Patients Pay More Than They ShouldIn this episode, Michael Grosberg, VP of Product Management at Model N, breaks down the complex drug pricing ecosystem—revealing how rebates, PBMs, and outdated pricing models shape what patients actually pay.You'll learn how Pharmacy Benefit Managers (PBMs) really operate, why list prices are misleading, and how pricing negotiations impact patient access. Michael also unpacks the mechanics behind patient assistance programs, the role of compounding and independent pharmacies, and how emerging technology can bring transparency and efficiency to a broken system.Whether you're in life sciences, healthcare tech, or just want to understand why your prescription costs what it does—this is a must-listen conversation.

What happens when a black belt, sword-slinging fitness icon gets cancer—twice? She picks up a camera and dares the universe to test her again.Ilaria Montagnani is not your average anything. She's been building strong bodies (and stronger minds) for over 30 years as the founder of Powerstrike. She's part Jane Fonda, part Uma Thurman, and very much the action hero you wish was your personal trainer.In this episode, we talk about what happens when everything you built your life on—movement, strength, purpose—gets sideswiped by disease. Twice. Ilaria opens up about diagnosis shock, bad doctor vibes, wielding swords post-mastectomy, and why working out through treatment is the best revenge.We get into scanxiety, menopause side effects, nutrition spirals, and the moment she realized the fitness industry needed more truth—and less bullshit.This one's real, raw, and will either guilt you into planking or inspire you to finally cancel that gym membership you've never used. Either way, you're gonna feel something.RELATED LINKSStronger for Life documentaryPowerstrike official siteIlaria on InstagramIlaria on LinkedInWorkout programs and DVDsForza Sword Workout on AmazonFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Product in Healthtech, we reconnect with Scott Martin, founder and CEO of Rescription, to discover how his company has evolved since our previous conversation.Topics covered:Rescription's "radical clarity" approach to transforming prescription drug costsHow Rescription leverages the 340B federal program as intended to benefit both health systems and patientsResults from partnerships with Bergen New Bridge and Baton Rouge General, showing 27-35% savingsWhy patients under Rescription's model receive zero-dollar copays for prescriptionsThe patent-pending adjudication technology developed with Vynyl that enables upfront processing at scaleRescription's ambitious expansion plans across 14 states and 15 additional health systemsKey moments:[01:16] Scott explains how Rescription's model differs from traditional PBMs[03:09] Clarifying misconceptions about the 340B program[05:14] Updates on partnerships with Bergen New Bridge and Baton Rouge General[07:25] How Rescription addresses pharmaceutical manufacturer pushback[09:24] Details on Rescription's patent-pending adjudication technology[11:15] Future expansion plans and new service offeringsResources mentioned:Wall Street Journal article featuring Rescription (link to be added)Follow Product in Healthtech:Website: productinhealthtech.comLinkedIn: Product in HealthtechEmail: info@productinhealthtech.com Product in Healthtech is community for healthtech product leaders, by product leaders. For more information, and to sign up for our free webinars, visit www.productinhealthtech.com.

This podcast will provide members with an analysis of the Trump Administration's Executive Order (EO) on drug pricing. We'll talk through what the EO means for the 340B program, the Inflation Reduction Act's negotiated drug pricing program, and site neutral payment, and what ASHP will be watching in the coming weeks.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Helene M. Epstein is not here to make friends with the healthcare system. She's here to dismantle the bullshit, one catastrophic medical error at a time. A marketing agency veteran turned patient safety firebrand, Helene's journey from copywriter to cancer misdiagnosis survivor, to “badass queen of patient safety,” is one hell of a ride.We talk about how her son was misdiagnosed over 15 times (yes, really), why some doctors should come with warning labels, and how American healthcare gaslights patients like it's a competitive sport. She also explains why she's giving away her new book for free, one chapter at a time, and how AI might actually be useful—if it stops hallucinating citations.This is not a light listen. It's the real deal. You'll walk away angry, inspired, and a lot more dangerous as a patient.RELATED LINKSHelene's Substack: https://helenemepstein.substack.comPatient Safety Resources: https://www.pfps.usSociety to Improve Diagnosis in Medicine: https://psnet.ahrq.gov/issue/society-improve-diagnosis-medicineHelene's Website: https://www.hmepstein.com/meet-heleneLinkedIn: https://www.linkedin.com/in/hmepsteinFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jonathan and Jennifer Wall didn't choose this path, but they're walking it with purpose. After losing their son, Zach, they turned their grief into action, founding Zach's Bridge, a lifeline for families navigating pediatric cancer. This episode isn't about platitudes or silver linings—it's about the raw, unfiltered reality of love and loss, the relentless unfairness of childhood cancer, and how the Walls are refusing to let their son's memory fade into the void.Jon and Jenn open up about what Zach taught them, how they've reshaped their lives in his honor, and why “Be Like Zach” isn't just a phrase—it's a call to action. We talk about the power of community, the frustrating gaps in pediatric cancer care, and how they're making sure no other family has to walk this road alone. If you've ever wondered what real resilience looks like, this is it.RELATED LINKS:Zach's BridgeZach's Rules for LifeBe Like Zach - SubstackJonathan Wall on LinkedInJon's Post: What Cancer Taught Me About WorkRett's Roost Blog - Jonathan's WritingZach's Story - OSIFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sarah Armstrong—forever Sarah Oakden to me, no matter what the legal documents say—isn't just my best friend. She's my first college friend, my musical theater soulmate, and the first person who truly saw me as an artist. She was there when I walked onto Binghamton's campus, and she was there when I walked into cancer hell. And, because we're nothing if not in sync, a few decades later, she got her own cancer badge of honor, and I was right there with her every step of the way.This episode is a love letter to friendship, music, and those moments that change your life forever. We nerd out over Sondheim, Binghamton's infamous "Theater 101 with Dr. Susan Peters." and the weird and wonderful rabbit holes that turn into entire alternate realities across decades of aging gracefully and falling with style.We talk about how cancer is the worst club with the best people and how surviving it together just adds another verse to the song we've been singing for 30 years. It's funny. It's real. It's a master class in love, laughter, and musicals that should have been bigger; with a big tip of the hat to Nancy Ford and Gretchen Cryer for their acclaimed musical "I'm Getting My Act Together and Taking It on the Road"Oh, and RIP to the legendary Denny's on Vestal Parkway. You will be missed.FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.